PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ARO-APOC3 IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME

Registry ID

AROAPOC3-3001

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ARROWHEAD PHARMACEUTICALS, INC.

Start date

2024-02-07

Completion date

2026-03-18

Last update

2021-11-29

Conditions

• FAMILIAL CHYLOMICRONEMIA SYNDROME

Related clinical trials

• AN OPEN-LABEL SAFETY STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) PREVIOUSLY TREATED WITH VOLANESORSEN (ISIS 304801)
• AN OPEN-LABEL EXTENSION STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

View on source registry